High R&D Costs Fueling Growth in Cancer Immunotherapy Drug Discovery Outsourcing Market: Critical Driver Shaping the Cancer Immunotherapy Drug Discovery Outsourcing Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Cancer Immunotherapy Drug Discovery Outsourcing Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the market size for outsourcing cancer immunotherapy drug discovery has shown swift growth. It is projected that the market will expand from $1.5 billion in 2024 to $1.68 billion in 2025, with a compound annual growth rate (CAGR) of 11.6%. The previous period's growth can be associated with an increase in adverse drug reaction cases, a rise in the demand for comprehensive genomic testing, an increase in global cancer incidences, a greater need for targeted therapy, and an escalating number of clinical trials.

Cancer Immunotherapy Drug Discovery Outsourcing Market Size Forecast: What's the Projected Valuation by 2029?
Accelerated growth is anticipated in the cancer immunotherapy drug discovery outsourcing market over the upcoming years. It is projected to expand to $2.57 billion in 2029 with an 11.3% compound annual growth rate (CAGR). This surge in the forecasted period is likely due to the heightened emphasis on individualized medicine, the increase in diagnostic tests, the amplified attention to personalized cancer therapies, the growth in healthcare spending, and the rise in cancer incidence and awareness. The forecasted period is expected to witness key trends, including advancements in diagnostic technology, the rise of next-generation sequencing (NGS), the adoption of artificial intelligence (AI), liquid biopsy technology developments, the creation of companion diagnostic devices at points-of-care, and the innovation of testing technologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-drug-discovery-outsourcing-global-market-report

What Are the Drivers Transforming the Cancer Immunotherapy Drug Discovery Outsourcing Market?
The rise in cancer immunotherapy drug discovery outsourcing market is anticipated to be fueled by the exorbitant expenses associated with research and development. The high cost is largely a result of the requirement for specialized skills, high-end equipment, and risks inherent in innovation. The practice of subcontracting drug discovery tasks taps into the benefits of large-scale operations provided by contract research organizations (CROs). This allows smaller biotech firms and start-ups to enhance their R&D spending efficiencies and direct resources more effectively, thereby improving cost-effectiveness. For example, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a representative body for the pharmaceutical industry in Europe, reported in June 2023 that total pharma R&D spending in Europe stood at $49,500 million (€44,500 million) in 2022. This was a roughly 6.45% increase from $46,500 million (€42,533 million) in 2021. Thus, the steep cost of conducting research and development in-house is stimulating the growth of the cancer immunotherapy drug discovery outsourcing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15528&type=smp

What Long-Term Trends Will Define the Future of the Cancer Immunotherapy Drug Discovery Outsourcing Market?
In the cancer immunotherapy drug discovery outsourcing market, leading entities are pursuing strategic partnerships to bolster the development of cancer medications and garner a competitive edge. Such partnerships largely involve a cooperative relationship between multiple organizations who merge their assets, skills, and endeavors to attain mutual targets. For example, in February 2022, Ono Pharmaceutical Co., Ltd., a pharmaceutical enterprise based in Japan, and Bristol-Myers Squibb, a biopharmaceutical firm based in the US, signed an outsourcing contract with Prime Research Institute for Medical Research, Inc., a Japan-based research facility, for a cooperative clinical research study targeting gastric cancer patients who have received treatment with Opdivo (nivolumab) in conjunction with chemotherapy. This cooperative venture funded by the industry constitutes a large-scale, multi-institution research using PRiME-R's data inputting mechanism, CyberOncology, which aids in the standardization, organization, administration, and incorporation of real-world data into everyday cancer treatment practices. Leveraging CyberOncology, this clinical study assesses the use of Opdivo alongside chemotherapy for untreated advanced or recurrent gastric cancer. It engages around 30 healthcare locations throughout the nation with the goal of streamlining data entry, boosting data precision, and hastening analysis.

Which Segments in the Cancer Immunotherapy Drug Discovery Outsourcing Market Offer the Most Profit Potential?
The cancer immunotherapy drug discovery outsourcing market covered in this report is segmented -

1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies And Cancer Vaccines, Other Drug Types
2) By Service Type: Target Identification And Validation, Lead Screening And Characterization, Cell-Based Assays
3) By Therapeutic Area: Lung Cancer, Breast Cancer, Melanoma, Other Therapeutic Areas

Subsegments:
1) By Monoclonal Antibodies: Checkpoint Inhibitors, Therapeutic Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
2) By Immunomodulators: Cytokines, Immune Checkpoint Modulators, Toll-Like Receptor Agonists, Immune Adjuvants
3) By Oncolytic Viral Therapies And Cancer Vaccines: Oncolytic Virus-Based Therapies, Cancer Vaccines, Viral Vectors For Immunotherapy
4) By Other Drug Types: Adoptive Cell Therapy, Immune Cell Modulators, Small Molecule Immune Modulators, Gene Editing And Immunotherapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15528&type=smp

Which Firms Dominate the Cancer Immunotherapy Drug Discovery Outsourcing Market by Market Share and Revenue in 2025?
Major companies operating in the cancer immunotherapy drug discovery outsourcing market are Thermo Fisher Scientific Inc., Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, WuXi AppTec Co Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Evotec SE, Shanghai ChemPartner Co. Ltd., Aragen Life Sciences Limited, GenScript Biotech Corporation, BGI Genomics Co. Ltd., NeoGenomics Laboratories Inc., ARUP Laboratories, Syngene International Limited, BioDuro-Sundia, Ambry Genetics Corporation, Selvita, Crown Bioscience International, CENTOGENE N.V., Jubilant Biosys, Oncodesign Services, Icagen Inc., Reaction Biology Corporation, ChemBridge Corporation

Which Regions Offer the Highest Growth Potential in the Cancer Immunotherapy Drug Discovery Outsourcing Market?
North America was the largest region in the cancer immunotherapy drug discovery outsourcing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy drug discovery outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15528

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.